E-DRUG: Feb 25, Webinar - TRIPS use by LDCs: policy space for innovation & access to medicines
--------------------------------------------------------------------------
Feb 25, Webinar - The implementation of the TRIPS Agreement by Least Developed Countries: preserving policy space for innovation and access to medicines
Dear all,
Please find below the invitation to the next webinar organized by the
Knowledge Network for Innovation and Access to Medicines, a project of the
Global Health Centre, Graduate Institute of Geneva. Recording of all
webinars of the series are available at
https://www.knowledgeportalia.org/webinars
The implementation of the TRIPS Agreement by Least Developed Countries:
preserving policy space for innovation and access to medicines
Thursday, February 25, 4pm - 5pm CET
To join the webinar, please register here:
https://us02web.zoom.us/webinar/register/7416130364720/WN_o0Fd2jWcST
Speaker:
Monirul Azam, Associate professor in Law, Södertörn University and Adjunct
faculty in Intellectual Property Law, Stockholm University
Discussant:
Sangeeta Shashikant, Coordinator Development and Intellectual Property
Programme, Third World Network
Research:
Monirul Azam. Intellectual Property and Public Health in the Developing
World. Chapter 5. Has the TRIPS Waiver Helped the Least Developed Countries
Progress Towards Innovation and Compliance?
Open Book Publishers. 2016.
https://www.openbookpublishers.com/product/476
The World Trade Organization's agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS) has established common minimum
standards of patent protection across the globe. Countries had different
transition periods to adapt to international rules according to their level
of development. Least Developed Countries (LDCs) had an extended period to
start applying TRIPS and patent protection in general (by 2021), with a
further extension specifically for pharmaceuticals (2033). With the general
transition period coming to an end and some countries ceasing to be in the
LDC category, how can national TRIPS implementation be done in a manner
protective of innovation and access to medicines?
Using the case study of Bangladesh, Dr. Monirul Azam will present a plan of
action developed to guide countries in their national implementation of the
TRIPS Agreement, identifying legal, technical and infrastructural changes
required. He will offer specific policy recommendations to comply with
international stipulations while still maintaining policies for the
development of local industry and integrating long-term innovation and
access objectives. Sangeeta Shashikant will then discuss the pharmaceutical
transition period and its implications for innovation and access to
medicines both within LDCs and globally.
The webinar is free and open to the public and will be held in English.
Participants can pose questions orally or in writing, and the speakers will
respond to a selection of these during the second half of the event.
Recordings of all webinars are made available at the Knowledge Portal on
Innovation and Access to Medicines. After registering, you will receive a
confirmation email with additional information on how to join the webinar
using the Zoom platform. This event is part of the webinar series of the
Knowledge Network for Innovation and Access to Medicines, a project of the
Global Health Centre at the Graduate Institute, Geneva.
Marcela Vieira, LLB, MPH
Researcher and Project Coordinator of the
Knowledge Network for Innovation and Access to Medicines
https://www.knowledgeportalia.org/
Global Health Centre, Research
Graduate Institute of International and Development Studies
marcela.vieira@graduateinstitute.ch